159 related articles for article (PubMed ID: 32338875)
1. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Zhang C; Wang X; Cheng R; Zhong Z
Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632
[TBL] [Abstract][Full Text] [Related]
4. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
[TBL] [Abstract][Full Text] [Related]
5. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
6. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Guo B; Wei J; Wang J; Sun Y; Yuan J; Zhong Z; Meng F
Acta Biomater; 2022 Jun; 145():200-209. PubMed ID: 35430336
[TBL] [Abstract][Full Text] [Related]
7. CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma.
Gu W; An J; Meng H; Yu N; Zhong Y; Meng F; Xu Y; Cornelissen JJLM; Zhong Z
Adv Mater; 2019 Nov; 31(46):e1904742. PubMed ID: 31560141
[TBL] [Abstract][Full Text] [Related]
8. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
[TBL] [Abstract][Full Text] [Related]
9. Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
Jackson S; Agbana P; Kim KB; Bae Y
J Pharm Sci; 2022 Apr; 111(4):1172-1177. PubMed ID: 34551351
[TBL] [Abstract][Full Text] [Related]
10. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib.
Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
[TBL] [Abstract][Full Text] [Related]
12. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
14. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model.
Varela-Moreira A; van Straten D; van Leur HF; Ruiter RWJ; Deshantri AK; Hennink WE; Fens MHAM; Groen RWJ; Schiffelers RM
Int J Pharm X; 2020 Dec; 2():100049. PubMed ID: 32490374
[TBL] [Abstract][Full Text] [Related]
15. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Jun Y; Xu J; Kim H; Park JE; Jeong YS; Min JS; Yoon N; Choi JY; Yoo J; Bae SK; Chung SJ; Yeo Y; Lee W
J Pharm Sci; 2020 Apr; 109(4):1615-1622. PubMed ID: 31945310
[TBL] [Abstract][Full Text] [Related]
18. Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.
Gadalla HH; Lee S; Kim H; Armstrong AT; Fathalla D; Habib F; Jeong H; Lee W; Yeo Y
J Control Release; 2022 Dec; 352():637-651. PubMed ID: 36349616
[TBL] [Abstract][Full Text] [Related]
19. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
20. Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
Federspiel JD; Codreanu SG; Goyal S; Albertolle ME; Lowe E; Teague J; Wong H; Guengerich FP; Liebler DC
Mol Cell Proteomics; 2016 Oct; 15(10):3233-3242. PubMed ID: 27503896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]